Investigation of Sage Therapeutics Underway
Glancy Prongay & Murray LLP, a prominent national law firm focused on protecting shareholder rights, has launched an investigation into Sage Therapeutics, Inc. (SAGE). This investigation aims to uncover potential violations of federal securities laws that may have resulted in considerable financial losses for investors who hold shares in the company.
Recent FDA Approvals Background
In a significant event in 2023, Sage announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for zuranolone, which is designed for treating postpartum depression (PPD). Notably, it was not approved for major depressive disorder (MDD), as there wasn't enough evidence to support its effectiveness for that condition. Following this news, Sage's stock plummeted by over 53%, leaving many investors reeling from the financial impact.
Challenges in Clinical Trials Ahead
Outcome of the Phase 2 Study for SAGE-718
In 2024, Sage disclosed that a Phase 2 trial for SAGE-718, meant to address mild cognitive impairment associated with Parkinson's Disease, did not achieve its primary effectiveness goals. Consequently, Sage chose to halt development of this treatment, resulting in an additional stock decline of nearly 20%. This series of unfavorable news surrounding Sage's clinical trials has sparked worries among investors regarding the company’s future product direction.
Findings from the Sage-324 Study
Similarly, the company reported unsatisfactory results from a Phase 2 trial of Sage-324, which was developed for essential tremor. The study failed to produce a meaningful response compared to the placebo, prompting Sage to cease further development of this drug. This announcement further depressed the stock price, contributing to the troubling trend of disappointing news the company has encountered.
Your Rights as an Investor
If you have experienced financial losses related to your Sage Therapeutics (SAGE) stocks, it's worth looking into your legal options. The legal team at Glancy Prongay & Murray LLP is actively inviting impacted investors to reach out and discuss potential avenues for recovery. They’re assessing the feasibility of filing claims based on federal securities laws for those who feel misled or inadequately informed regarding their investments.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP is well-known for advocating for investors, having participated in numerous high-profile cases. The firm boasts a strong track record in securities litigation, achieving impressive settlements for clients across various industries. With a seasoned team committed to holding corporations accountable for their actions, they ensure that investors are protected.
Frequently Asked Questions
What’s the latest on the Sage Therapeutics investigation?
The investigation is currently underway and focuses on possible violations of federal securities laws that occurred after significant declines in stock value.
How did the FDA's decision impact Sage's stock performance?
The FDA’s conditional approval of zuranolone led to a sharp decline in Sage's stock, significantly affecting investors’ financial positions.
What should investors do if they suffered losses?
Investors may have the right to pursue claims to recover their losses and are encouraged to contact Glancy Prongay & Murray LLP for support.
What were the outcomes of Sage's recent clinical trials?
The outcomes of the recent trials for SAGE-718 and Sage-324 were disappointing, resulting in halted developments and further decreases in stock prices.
Why is it essential to report non-public information?
Whistleblower programs play a crucial role in allowing individuals with inside knowledge to reveal corporate misconduct, which can lead to significant financial recovery for investors.
